Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michail Vikelis

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
Expert Review of Neurotherapeutics|January 30, 2025
Switching between anti-CGRP monoclonal antibodies in migraine prophylaxisMichail Vikelis, Dimitrios Rikos, Andreas A Argyriou, et al.
European Journal of Neurology|February 11, 2023
Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real-world data from a Greek registryAndreas A Argyriou, Emmanouil V Dermitzakis, Georgia Xiromerisiou, et al.
BMC Neurology|May 20, 2017
Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical studyMichail Vikelis, Emmanouil V Dermitzakis, Konstantinos C Spingos, et al.
Journal of Clinical Medicine|May 13, 2023
Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek RegistryAndreas A Argyriou, Emmanouil V Dermitzakis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine|December 30, 2025
Testing the Efficacy of Eptinezumab 100 mg in the Early Prevention of Chronic Migraine over Weeks 1 to 4: Prospective Real-World Data from the GRASP Study GroupAndreas A Argyriou, Emmanouil V Dermitzakis, Maria Chondrogianni, et al.
Toxins|February 23, 2024
Effects of OnabotulinumtoxinA on Allodynia and Interictal Burden of Patients with Chronic MigraineAndreas A Argyriou, Emmanouil V Dermitzakis, Dimitrios Rikos, et al.
Toxins|September 27, 2023
Single OnabotulinumtoxinA Session Add-On to Carbamazepine or Oxcarbazepine in Treatment-Refractory Trigeminal Neuralgia: A Case Series with 24-Week Follow UpGeorgia Xiromerisiou, Ioannis C Lampropoulos, Emmanouil V Dermitzakis, et al.
Acta Neurologica Scandinavica|July 18, 2020
Meta-analysis of melatonin levels in cluster headache-Review of clinical implicationsIoannis Liampas, Vasileios Siokas, Alexandros Brotis, et al.
Journal of Molecular Neuroscience : MN|September 14, 2021
VDR Gene Polymorphisms and Cluster Headache Susceptibility: Case-Control Study in a Southeastern European Caucasian PopulationMaria Papasavva, Michail Vikelis, Vasileios Siokas, et al.
Journal of Clinical Medicine|January 23, 2024
Nine-Month Continuous Fremanezumab Prophylaxis on the Response to Triptans and Also on the Incidence of Triggers, Hypersensitivity and Prodromal Symptoms of Patients with High-Frequency Episodic MigraineEmmanouil V Dermitzakis, Michail Vikelis, Georgia Xiromerisiou, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Expert Review of Neurotherapeutics|January 30, 2025
Switching between anti-CGRP monoclonal antibodies in migraine prophylaxisMichail Vikelis, Dimitrios Rikos, Andreas A Argyriou, et al.
European Journal of Neurology|February 11, 2023
Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real-world data from a Greek registryAndreas A Argyriou, Emmanouil V Dermitzakis, Georgia Xiromerisiou, et al.
BMC Neurology|May 20, 2017
Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical studyMichail Vikelis, Emmanouil V Dermitzakis, Konstantinos C Spingos, et al.
Journal of Clinical Medicine|May 13, 2023
Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek RegistryAndreas A Argyriou, Emmanouil V Dermitzakis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine|December 30, 2025
Testing the Efficacy of Eptinezumab 100 mg in the Early Prevention of Chronic Migraine over Weeks 1 to 4: Prospective Real-World Data from the GRASP Study GroupAndreas A Argyriou, Emmanouil V Dermitzakis, Maria Chondrogianni, et al.
Toxins|February 23, 2024
Effects of OnabotulinumtoxinA on Allodynia and Interictal Burden of Patients with Chronic MigraineAndreas A Argyriou, Emmanouil V Dermitzakis, Dimitrios Rikos, et al.
Toxins|September 27, 2023
Single OnabotulinumtoxinA Session Add-On to Carbamazepine or Oxcarbazepine in Treatment-Refractory Trigeminal Neuralgia: A Case Series with 24-Week Follow UpGeorgia Xiromerisiou, Ioannis C Lampropoulos, Emmanouil V Dermitzakis, et al.
Acta Neurologica Scandinavica|July 18, 2020
Meta-analysis of melatonin levels in cluster headache-Review of clinical implicationsIoannis Liampas, Vasileios Siokas, Alexandros Brotis, et al.
Journal of Molecular Neuroscience : MN|September 14, 2021
VDR Gene Polymorphisms and Cluster Headache Susceptibility: Case-Control Study in a Southeastern European Caucasian PopulationMaria Papasavva, Michail Vikelis, Vasileios Siokas, et al.
Journal of Clinical Medicine|January 23, 2024
Nine-Month Continuous Fremanezumab Prophylaxis on the Response to Triptans and Also on the Incidence of Triggers, Hypersensitivity and Prodromal Symptoms of Patients with High-Frequency Episodic MigraineEmmanouil V Dermitzakis, Michail Vikelis, Georgia Xiromerisiou, et al.
Pageof 7